MERLIN Biotech
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3805 Old Easton Rd, Doylestown, Pennsylv...Website
www.merlinbiotech.comRevenue
<$5 MillionIndustry
About MERLIN Biotech
Merlin Biotech specializes in developing novel therapeutics using clinically-proven mRNA technology, aiming to address diseases with limited treatment options. The company focuses on harnessing the potential of mRNA to treat a wide range of diseases, with its lead program, MER-101, targeting adult solid cancers and Ewing sarcoma. By activating multiple immunostimulatory pathways, MER-101 seeks to enhance the immune system's ability to detect and combat cancer. Merlin Biotech is committed to advancing innovative cancer immunotherapies and has garnered attention through recent investments and presentations at industry events.Explore more
SIC Code 28,283NAICS Code 32,325Show moreMERLIN Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to MERLIN Biotech
Compare insights from companies similar to MERLIN Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
MERLIN Biotech
<$5M
11-50
Private
<$5M
-
IH
Ian HenrichCo-Founder & Vice President, Research & Development
MERLIN Biotech Tech Stack
A closer look at the technologies used by MERLIN Biotech
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MERLIN Biotech
Sign Up For FreeTo access detailed company insights
Merlin Biotech specializes in developing novel therapeutics using clinically-proven mRNA technology, aiming to address diseases with limited treatment options. The company focuses on harnessing the potential of mRNA to treat a wide range of diseases, with its lead program, MER-101, targeting adult solid cancers and Ewing sarcoma. By activating mult... Read More
